What newly brought endocrinology by the past 2022?
https://doi.org/10.14341/probl13261
Abstract
In the past year, the Federal Project “Fight against Diabetes” 2023–2030 was developed in detail and submitted in detail and submitted to the Government of the Russian Federation, which will significantly improve the practice of working with patients with diabetes, providing them with maximum availability of medical care, including in updated and technologically re -equipped regional endocrinological centers, reviving the active work of “Diabetes schools”, “Diabetic foot” rooms, diagnostic laboratories, introducing new forms of communication with patients, including using personal assistants of a doctor, continuous technologies for monitoring glycemia, etc.
About the Authors
G. A. Melnichenko
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Galina A. Melnichenko - MD, PhD, Academician of the Russian Academy of Sciences.
Moscow
Competing Interests:
None
M. V. Shestakova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Marina V. Shestakova - MD, PhD, Professor, Academician of the Russian Academy of Sciences.
Moscow
Competing Interests:
None
References
1. Hirsch JS. FDA approves teplizumab: a milestone in type 1 diabetes. Lancet Diabetes Endocrinol. 2023;11(1):18. doi: https://doi.org/10.1016/S2213-8587(22)00351-5
2. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. doi: https://doi.org/10.1016/S0140-6736(21)01324-6
3. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: FIDELITY pooled analysis. EurHeart J. 2022;43(6):474-484. doi: https://doi.org/10.1093/eurheartj/ehab777
4. González-Juanatey JR, Górriz JL, Ortiz A, et al. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023;55(1):502-513. doi: https://doi.org/10.1080/07853890.2023.2171110
5. Crespo-Trevino R, Schiffman J, Ugradar S, et al. Thyroid dermopathy responds to teprotumumab therapy. Endocrinol Diabetes Metab Case Reports. 2022;2022(10295):143-155. doi: https://doi.org/10.1530/EDM-21-0201
6. Gadelha M, Bex M, Feelders RA, et al. Randomized trial of osilodrostat for the treatment of cushing disease. J Clin Endocrinol Metab. 2022;107(7):e2882-e2895. doi: https://doi.org/10.1210/clinem/dgac178
7. Fleseriu M, Newell-Price J, Pivonello R, et al. Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension. Eur J Endocrinol. 2022;187(4):531-541. doi: https://doi.org/10.1530/EJE-22-0317
8. Walia R, Gupta R, Bhansali A, et al. Molecular imaging targeting corticotropin-releasing hormone receptor for corticotropinoma: A changing paradigm. J Clin Endocrinol Metab. 2021;106(4):1816-1826. doi: https://doi.org/10.1210/clinem/dgaa755
9. Gadelha MR, Gordon MB, Doknic M, et al. ACROBAT edge: Safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly. J Clin Endocrinol Metab. 2022;106(4):1816-1826. doi: https://doi.org/10.1210/clinem/dgac643
10. Zhao J, Wang S, Markison S, et al. Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist. ACS Med Chem Lett. 2023;14(1):66-74. doi: https://doi.org/10.1021/acsmedchemlett.2c00431
11. Sarafoglou K, Barnes CN, Huang M, et al. Tildacerfont in adults with classic congenital adrenal hyperplasia: Results from two phase 2 studies. J Clin Endocrinol Metab. 2021;106(11):e4666-e4679. doi: https://doi.org/10.1210/clinem/dgab438
12. Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859-868. doi: https://doi.org/10.1016/S2213-8587(22)00277-7
13. Auchus RJ, Sarafoglou K, Fechner PY, et al. Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2022;107(3):801-812. doi: https://doi.org/10.1210/clinem/dgab749
14. Chan ML, Qi Y, Larimore K, et al. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. Clin Pharmacokinet. 2022;61(2):263-280. doi: https://doi.org/10.1007/s40262-021-01059-1
15. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530. doi: https://doi.org/10.1056/NEJMoa1913805
16. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi: https://doi.org/10.1056/NEJMoa1912387
Review
For citations:
Melnichenko G.A., Shestakova M.V. What newly brought endocrinology by the past 2022? Problems of Endocrinology. 2023;69(1):4-7. (In Russ.) https://doi.org/10.14341/probl13261
Views:
1827
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
